acute myeloid leukemia with t(8;16)(p11;p13) translocation

Acute myeloid leukemia with t(8;16)(p11;p13) translocation is a distinct type of blood cancer that is defined by a specific chromosomal change. This genetic abnormality can appear as a new event or develop as a therapy-related change in people with AML. The abnormal translocation influences how blood cells develop, resulting in a disease with unique features. People with this condition often have disease involvement outside the bone marrow. This extramedullary involvement may include an enlarged liver, spleen, and lymph nodes, as well as skin lesions. There is also a risk of severe blood clotting problems, such as disseminated intravascular coagulopathy or primary fibrinolysis, which further complicates the condition.

Common signs and symptoms include organ enlargement such as hepatomegaly (enlarged liver) and splenomegaly (enlarged spleen), swollen lymph nodes, and skin infiltrations. Some people may experience involvement of the gums, bones, the central nervous system, and other organs. A severe blood clotting disorder is also a frequent finding.

This condition is associated with a chromosomal translocation known as t(8;16)(p11;p13). The abnormality can occur suddenly or after prior therapy for another cancer. This genetic change leads to the development of abnormal blast cells with a myelomonocytic stage of differentiation. Information about additional risk factors is currently limited for this condition.

Information about treatment is currently limited for this condition.

The prognosis for people with this condition is generally poor. The aggressive nature of the disease, combined with complications such as severe clotting disorders, contributes to a challenging outlook. However, outcomes can vary among different individuals.

Information about research is currently limited for this condition.